The Competition Commission of Pakistan (CCP) has fined a Rs. 150 million penalty on Reckitt Benckiser Pakistan Ltd for deceptive marketing and misleading advertising of its flagship Product ‘Strepsils’.
CCP’s conducted an inquiry which concluded that marketing campaign of the respondent seems to be deceptive in terms of Section 10 of the Competition Act in general, that restricts distribution of false and misleading information to consumers.
Previously a formal complaint was filed with CCP, alleging that Reckitt Benckiser Pakistan Limited had been promoting misleading information to the consumers by giving an impression that its product Strepsils was a Medical drug for sore throat and cough, however, Strepsils was de-registered as a drug in 2005 and categorized as ‘Non-medicated Lozenges’.
The CCP inquiry has conveyed that efforts made by Reckitt Benckiser Pakistan to inform the general public about change in the formula of Strepsils were inadequate as it merely prints ‘Non-Medicated Lozenges’.
Latest posts by News Desk (see all)
- FBR asked to enhance efforts for Broadening Tax Net - May 27, 2023
- National Savings Rate for June-2023 - May 27, 2023
- Islamabad to get a new “Luxury Resort” - May 27, 2023
